Trials / Completed
CompletedNCT03966079
Thrombolysis Endovascular Treatment of Pulmonary Embolism
Single-dose rtPA Thrombolysis Endovascular Treatment of Pulmonary Embolism With Right Ventricular Dysfunction:a Pilot Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Beijing Tsinghua Chang Gung Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of endovascular thrombolysis of pulmonary embolism with right ventricular dysfunction with single-dose rtPA
Detailed description
The patients with right ventricular dysfunction who are diagnosed by CT pulmonary angiography will receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the in this study. The Change of RV to LV Diameter Ratio,Rate of death,rate of major bleeding,pulmonary embolism recurrence at 1month will be reviewed to assess the efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant tissue plasminogen activator | Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-01-31
- Completion
- 2020-01-31
- First posted
- 2019-05-29
- Last updated
- 2020-11-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03966079. Inclusion in this directory is not an endorsement.